12:00 AM
 | 
Dec 18, 2000
 |  BC Week In Review  |  Company News  |  Deals

Actelion, Genentech deal

ATLN will develop and co-promote with DNA in the U.S. its Tracleer bosentan endothelin receptor antagonist. ATLN will receive an upfront...

Read the full 92 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >